

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/531,662	RATCLIFFE ET AL.	

Examiner	Art Unit	
ALEXANDER D. KIM	1656	

All Participants:

Status of Application: _____

(1) ALEXANDER D. KIM.

(3) Sulay Jhaveri.

(2) Mark D. Sweet.

(4) _____.

Date of Interview: 2 November 2009

Time: _____

Type of Interview:

Telephonic
 Video Conference
 Personal (Copy given to: Applicant Applicant's representative)

Exhibit Shown or Demonstrated: Yes No

If Yes, provide a brief description: .

Part I.

Rejection(s) discussed:

NA

Claims discussed:

NA

Prior art documents discussed:

NA

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

/Alexander D Kim/
Examiner, Art Unit 1656

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The Examiner has noted following changes are required to the instant specification to remove any issues in regard to the sequence compliance: (A) the specification filed on 12/19/07, bottom, replace "SEQ ID NO: 2" to ---residues 6-14 of SEQ ID NO: 1---; (B) specification filed on 4/14/09 in table 2, description, replace "SEQ ID NOS 4-29" to ---SEQ ID NOS: 4-14, 16-17 and 19-29---; (C) amend the SEQ ID NO: 14 by adding the amino acid residues SEQ ID NO: 15 at the C-terminal of SEQ ID NO: 14; and amend SEQ ID NO: 17 by adding the residues of SEQ ID NO: 18 at the C-terminal end of SEQ ID NO: 17, because the amino acid residues shown in Table 2 are contiguous amino acids even though they are separated by gaps which were necessitated for the alignment. (D) add missing "Val Asn" in the C-terminal of SEQ ID NO: 31.